Illness management and recovery:one-year follow-up of a randomized controlled trial in Danish community mental health centers: long-term effects on clinical and personal recovery by Jensen, Sofie Bratberg et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Illness management and recovery
Jensen, Sofie Bratberg; Dalum, Helle Stentoft; Korsbek, Lisa; Hjorthøj, Carsten; Mikkelsen,
John Hagel; Thomsen, Karin; Kistrup, Kristen; Olander, Mette; Lindschou, Jane; Mueser, Kim
T; Nordentoft, Merete; Eplov, Lene Falgaard
Published in:
BMC Psychiatry
DOI:
10.1186/s12888-019-2048-0
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Jensen, S. B., Dalum, H. S., Korsbek, L., Hjorthøj, C., Mikkelsen, J. H., Thomsen, K., ... Eplov, L. F. (2019).
Illness management and recovery: one-year follow-up of a randomized controlled trial in Danish community
mental health centers: long-term effects on clinical and personal recovery. BMC Psychiatry, 19, [65].
https://doi.org/10.1186/s12888-019-2048-0
Download date: 03. Feb. 2020
RESEARCH ARTICLE Open Access
Illness management and recovery: one-year
follow-up of a randomized controlled trial
in Danish community mental health
centers: long-term effects on clinical and
personal recovery
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Karin Thomsen5, Kristen Kistrup6, Mette Olander7, Jane Lindschou8, Kim T. Mueser9, Merete Nordentoft3 and
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Abstract: Background: Illness Management and Recovery (IMR) is a curriculum-based rehabilitation program for
people with severe mental illness with the short-term aim of improving illness self-management and the long-term
aim of helping people achieve clinical and personal recovery.
Method: Participants with schizophrenia or bipolar disorders were recruited from three community mental health
centers in the Capital Region of Denmark and randomized to receive group-based IMR and treatment as usual or
only the usual intervention. All outcomes were assessed at baseline, postintervention, and the one-year follow-up.
Long-term outcomes were categorized according to clinical recovery (i.e., symptoms, global functioning, and
hospitalization) and personal recovery (i.e., hope and personal agency). Generalized linear mixed model regression
analyses were used in the intent-to-treat analysis.
Results: A total of 198 participants were included. No significant differences were found between the IMR
and control groups in the Global Assessment of Functioning one year after the intervention, nor were there
significant differences in symptoms, number of hospital admissions, emergency room visits, or outpatient
treatment.
Conclusion: The present IMR trial showed no significant effect on clinical and personal recovery at the
one-year follow-up. Together with the results of other IMR studies, the present study indicates that the
effect of IMR on symptom severity is unclear, which raises questions regarding the impact of IMR on
functioning. Additionally, IMR did not affect personal recovery. Although more research is needed, the
results indicate that the development of other interventions should be considered to help people with
severe mental illness achieve a better level of functioning and personal recovery.
Trial registration: Trial registered at http://www.clinicaltrials.gov (NCT01361698).
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Background
The Illness Management and Recovery (IMR) program
is a manualized, curriculum-based, recovery-oriented,
rehabilitation program for people with schizophrenia or
a major mood disorder [1]. Typically, IMR is delivered
by mental healthcare professionals with an aim of help-
ing individuals set and pursue personal recovery goals
and learn illness management skills to facilitate their at-
tainment of these goals [1]. Clinical recovery refers to a
reduction in the signs and symptoms of the mental ill-
ness and restoration of cognitive, social, and occupa-
tional functioning, whereas personal recovery refers to
the process of constructing a personally meaningful life
within and beyond the limits of one’s mental illness [2–
5]. The IMR program is based on two theoretical
models: the transtheoretical model and the
stress-vulnerability model. The transtheoretical model
proposes that motivation to change develops over a
series of stages (precontemplation, contemplation, prep-
aration, action, maintenance) and that facilitating change
requires stage-specific interventions. The stress-vulner-
ability model posits that the course and outcome of
schizophrenia is determined by the dynamic interplay of
biological vulnerability, stress, and coping. The
IMR-program is aimed at interrupting the cycle of stress
and vulnerability that leads to relapse and poor function-
ing [1, 4, 6]. Therefore, the long-term outcomes of IMR
are to improve both personal and clinical recovery, as il-
lustrated in Fig. 1.
The present study focuses on the long-term effects of
the IMR program. The literature review on the IMR pro-
gram by McGuire et al. (2014) [7] found two random-
ized clinical trials (RCTs) [8, 9] and one quasi-
experimental trial [10] with results on the long-term ef-
fects of IMR. Two subsequent RCTs examined the
long-term effects of IMR [11, 12], and one RCT pre-
planned a long-term follow-up but instead conducted a
qualitative study at one year of follow-up [13]. Three of
the trials revealed that the participants who received
IMR had greater reductions in symptoms and increases
in functioning posttreatment than those who received
the usual services and that they maintained these im-
provements during follow-up [8, 9, 12]. However, all
three trials had methodological limitations, such as not
establishing a primary outcome, conducting assessments
with nonblinded interviewers, and failing to perform a
sample size calculation. In contrast, two RCTs by Salyers
et al. (2010/2014) reported no group differences in favor
of IMR at either the posttreatment or follow-up time
points [10, 11]. However, these two RCTs also had meth-
odological limitations (i.e., not including assessor-
blinded interviews and primary outcomes, as noted
below). The early systematic review concluded that the
IMR-program was an effective intervention, but later
studies have cast doubt.
Two important issues must be considered when evalu-
ating research on the IMR-program. The first issue is ex-
posure to IMR, which can be measured by the number
of IMR sessions attended. The second issue is fidelity to
the principles of the IMR program, which can be mea-
sured with the IMR Fidelity Scale [14]. One RCT that
also used a modified IMR (i.e., it excluded three IMR
modules) did not report the number of sessions attended
or the fidelity score [15]. Another RCT reported a high
degree of exposure to IMR; however, the study did not
perform fidelity assessments, which limited the ability to
estimate the quality of IMR implementation [9]. Levitt et
al. (2009) reported high fidelity but a lower degree of ex-
posure than Färdig et al. (2011), with 54% of participants
attending more than 20 sessions [8, 9]. The two studies
by Salyers et al. (2010/2014) showed a good to high fi-
delity score; however, the authors reported low exposure
to IMR [10, 11]. Together, the five RCTs had limitations
in either IMR exposure or fidelity assessment.
The present RCT was designed to improve upon the
methodological limitations of previous IMR research
and to evaluate whether participants in the IMR pro-
gram exhibited improved clinical and personal recovery
and illness management postintervention and at the
one-year follow-up [16]. The IMR program was imple-
mented with high fidelity but, unfortunately, with lower
exposure to IMR than desired and reported in the study
Fig. 1 Hypothesized short-term and long-term outcome of the Illness Management and Recovery Program
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by Levitt et al. (2009), with 47% of the participants at-
tending more than 20 sessions. No differences in any
postintervention outcomes were found [17]. This article
reports the one-year follow-up outcomes for clinical and
personal recovery.
Methods
Design
This study was a prospective, assessor-blinded, RCT per-
formed in three community mental health centers
(CMHCs) in the Capital Region of Denmark, which
covers a population of approximately 1.8 million people.
The IMR program was provided as an add-on to treat-
ment as usual (TAU) care in the intervention group. The
trial design is described in detail elsewhere and therefore
will only be described briefly here [16]. Participants were
included from March 2011 to December 2013. Assess-
ments were conducted at baseline, posttreatment, and
one year following the end of treatment, with follow-up
data collection conducted between December 2013 and
December 2014. The present article focuses on the
one-year follow-up data.
Participants
We included participants based on diagnostic interviews
with the Present State Examination [18] conducted by a
psychiatrist or trained psychologist to verify the diagno-
sis of schizophrenia (F20.x) or bipolar disorder (F31.x)
according to the ICD-10 criteria. Additional inclusion
criteria were as follows: a) 18 years of age or older, b)
sufficient fluency in Danish to participate in the IMR
program, and c) willingness to provide informed con-
sent. The exclusion criteria were as follows: a) having a
guardian or a forensic arrangement, b) meeting the cri-
teria for the ICD-10 diagnosis of dementia or mental re-
tardation, c) having an active substance use disorder, d)
living in a community residential home, or e) being in-
volved in a psychoeducational course at the time of
inclusion.
Randomization and blinding
Patients were recruited from three CMHCs in the Cap-
ital Region of Denmark. Diagnostic eligibility for the
study was established with the Present State Examin-
ation (PSE) administered by a trained psychiatrist or a
psychologist [16, 17]. The randomization was performed
centrally and by telephone by the Copenhagen Trial Unit
to conceal the allocation sequence. The allocation se-
quence was computer-generated using permuted blocks
in varying sizes of 6, 8, and 10. The level of blinding at
the one-year follow-up was focused on the
assessor-blinded interviews, because blinding at the data
analysis level was compromised during the posttreat-
ment investigation.
Interventions
The IMR program
Participants randomized to the IMR intervention group
were offered an IMR course in addition to TAU as pro-
vided by CMHCs in the Capital Region of Denmark.
The IMR program lasted 9 months with weekly group
sessions, and each closed-enrollment group included ten
patients. The group sessions were conducted by two or
three clinicians at CMHCs. All patients receiving IMR
were given educational hand-outs corresponding to the
eleven different module topics (see Table 1).
Treatment as usual (TAU)
TAU consisted of an individually adapted interdisciplin-
ary treatment containing medication, individual case
manager support, individual and group therapy, and un-
standardized psychoeducation. The staff of the CMHCs
were trained mental health professionals, including
nurses, psychiatrists, psychologists, physiotherapists, oc-
cupational therapists, and licensed social workers. Every
patient in the CMHC had a case manager who together
with the patient selected the elements of the individual’s
treatment plan. The patient met with the case manager
once a week (or more or less frequently depending on
the state and preference of the patient) [16, 17].
IMR Fidelity scale
The IMR fidelity assessments were performed four
months after initiating the study and again at the end of
each IMR group. Staff specially trained in IMR fidelity
assessment from one participating community mental
health centers was conducting the assessments at the
other community mental health centers’ groups and vice
versa. A multiple data approach was used including: in-
terviews, observation of the IMR group, an audit of the
patient’s service records as well as audit of the IMR
notes of progress. Two raters independently scored each
Table 1 Modules in the Illness Management and Recovery
Program
Module Theme
1 Recovery strategies
2 Practical facts about mental illness
3 The Stress-Vulnerability Model
4 Building social support
5 Using medication effectively
6 Drug and alcohol use
7 Reducing relapses
8 Coping with stress and common problems
9 Coping with symptoms
10 Getting your needs met in the mental health system
11 Healthy Lifestyles
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session and then discussed any discrepancies and
reached a consensus rating.
Outcomes
The assessment of clinical recovery (i.e., functioning and
symptoms) was conducted through interviews with an
assessor who was blinded to the treatment group alloca-
tion. Assessment of personal recovery was obtained
through the participants’ self-reports. Information on ill-
ness management and recovery was obtained by the staff
and was self-reported by the participants. All outcomes
were assessed postintervention and again at the one-year
follow-up. The primary outcome was the Global Assess-
ment of Functioning (GAF) assessed by the GAF-F post-
intervention. Therefore, all one-year follow-up outcomes
are secondary or explorative outcomes.
The GAF is a generic rating scale ranging from 1 (low-
est) to 100 (highest) that was developed as an overall
measure of the patient’s social, psychological, and occu-
pational functioning. The GAF can be rated with a single
score that reflects both the symptom severity and func-
tional impairment or with separate scores for symptoms
(GAF-S) and functioning (GAF-F) [19]. For the present
study, both the GAF-F and GAF-S scores were obtained.
The Personal and Social Performance (PSP) scale mea-
sures social functioning within four domains: socially
useful activities, personal and social relationships,
self-care, and disturbing and aggressive behavior. The
PSP provides a score between one and one hundred
using a six-point severity scale for each domain. The rat-
ings are based on the outcome of a structured clinical
interview. A high score indicates higher personal and so-
cial functioning [20].
The Positive and Negative Syndrome Scale (PANSS) is
a semi-structured interview pertaining to the patient’s
symptoms over the past month [21, 22]. The PANSS in-
cludes 30 items with a seven-point rating that represents
increasing levels of psychopathology. The PANSS in-
cludes three subscales: the Positive Scale (7 items), the
Negative Scale (7 items), and the General Psychopath-
ology Scale (16 items). The PANSS total and subscales
scores are calculated by summing the ratings of all items
on the total scale and each subscale (range for total: 30–
210, range for Positive and Negative Scales: 7–49, and
range for General Psychopathology Scale: 16–112) [22].
The 6-item Hamilton Rating Scale for Depression
(HAM) is an interview-based measure of depression that
includes the following six items: depressed mood, work
and activities, sleep disturbance, guilt, anxiety, and re-
tardation [23]. The HAM-D6 is interview-based and
clinician-rated on a five-point scale (0–4), except for
sleep disturbance, which is rated on a three-point scale
(0–2). The HAM-D6 minimum score is zero, and the
maximum score is 22.
The Young Mania Rating Scale (YMRS) are composed
of the following 11 item scale as follows: 1. Elevated
Mood, 2. Increased Motor Activity-Energy, 3. Sexual
Interest, 4. Sleep, 5. Irritability, 6. Speech Rate and
Amount, 7. Language Thought Disorder, 8. Content, 9.
Disruptive-Aggressive Behavior, 10. Appearance, and 11.
Insight [24]. The YMRS is a clinician-rated instrument
that is used to assess the severity of mania; items 1, 2, 3,
4, 7, 10, and 11 use a five-point scale, and items 5, 6, 8,
and 9 use a nine-point scale. The YMRS minimum score
is zero, and the maximum score is sixty [25].
The IMR scale (IMRS) was developed to measure illness
self-management outcomes based on the stress-vulnerabil-
ity model and is an integrated part of the IMR program’s
Implementation Toolkit. Each item is rated on a five-point
scale, with lower scores reflecting lower levels of illness
management. The IMRS can be scored by summing up all
items on the scale for the total score (range: 15–75) or for
three subscales based on factor analyses with a three-factor
solution for the subscales (Recovery scale, Management
scale, and Biology scale) [13, 26].
The Mental Health Recovery Measure (MHRM) is a
self-reported 30-item scale that assesses perceived recov-
ery for individuals with a serious mental illness [27]. The
items are rated on a five-point scale ranging from zero
(strongly disagree) to four (strongly agree), creating a
total score range of zero to 120. Higher MHRM scores
indicate higher self-reported levels of mental health
recovery.
The Adult Hope Scale is a self-reported six-item scale
that assesses the level of hope. The items are assessed
using an eight-point Likert scale ranging from definitely
false to definitely true [28]. The measure consists of two
subscales: agency (goal determination) and pathways (ex-
tent of belief in ability to achieve goals). The Hope Scale
minimum score is six, and the maximum score is 48.
The Client’s Satisfaction Questionnaire measures the
participants’ satisfaction with community mental health
treatment [29], with a score range of 8–32.
Finally, we collected data from the following national
registers for all participants regarding their service
utilization: the Civil Registration System (CPR-register),
Danish Psychiatric Central Research Register (PCRR),
Danish Register of Causes of Death, and Danish National
Patient Register-Psychiatry [30]. We collected data on
the number of hospital admissions, length of admissions
in days, and number of emergency service visits. Every
inhabitant of Denmark is given a unique ten-digital per-
sonal identification number, and therefore, complete
follow-up using national databases is possible.
Statistical analysis
A detailed statistical analysis plan was created before
performing any analyses. The sample size calculation
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was conducted for the posttreatment investigation but
not for the one-year follow-up. The analyses were con-
ducted according to the intent-to-treat principle, with
the two-tailed level of significance for all statistical tests
set at 0.05. For the one-year follow-up analyses, we used
generalized linear mixed-effects regression analyses. The
relative changes in the GAF-F and social scores, psychi-
atric symptoms and illness management, and recovery
were evaluated postintervention and at the one-year
follow-up using the baseline data as covariates. Missing
data were handled through multiple imputations, which
were conducted with a linear mixed model, with
post-intervention and follow-up as repeated measure-
ments, baseline as a fixed effect covariate, and an un-
structured covariance matrix. We assumed and
estimated a time trend for the measures for the postin-
tervention and one-year follow-up measurements. Fur-
thermore, the linear mixed models were selected for
their capacity to handle missing longitudinal data. The
fixed values were the baseline values of GAF-F, GAF-S,
PSP, PANSS, subscale PANSS, Negative Scale, Subscale
PANSS Positive Scale, Subscale PANSS General Psycho-
pathology Scale, HAM-D6, YMRS, CSQ, IMRS-P,
IMRS-S, AHS, randomizing, sex, age, diagnosis, and
CMHC. The automatic procedure in SPSS to produce
missing imputed data values was used with 100 imput-
ation estimates. Outliers were identified through Cooks’
D Diagram, and all outliers were included in all analyses.
Residuals were tested for normality, linearity, and homo-
scedasticity, including using Spearman’s rank-order cor-
relation. Also, complete case analysis was conducted
where it is assumed that the missing data are missing
completely at random and excluded in the analysis. In
complete case analysis it is presumed to describe data
where the observed complete cases are representative of
the sample [31].
The per-protocol analysis was performed to explore
whether attendance at the IMR groups influenced the
results. One-way ANOVA was conducted to evaluate at-
tendance at the IMR groups as a continuous variable
and to treat attendance as a dichotomous variable (0–10
sessions vs. > 10 sessions); the latter measure was used
for non-exposure vs. exposure. Subgroup analyses were
conducted to evaluate whether the diagnosis or sex
interacted with treatment for the secondary outcomes.
In addition, a post hoc analysis was performed to de-
termine whether the subscale measurements of symp-
toms were influenced by IMR attendance as shown in
other trials using one-way ANOVA [26]. The other post
hoc analysis analyzed the IMRS as a three-factor solu-
tion. Also, we examined within-group changes at
long-term follow-up by linear mixed model, with
post-intervention and follow-up as repeated measure-
ments, baseline as a fixed effect covariate, and an
unstructured covariance matrix only focusing on time
effect within groups.
Poisson regression analysis was used for the count out-
comes (i.e., hospital admission, emergency room visits,
and outpatient treatment). Descriptive analyses were
used to explore whether the data were zero-inflated, and
a negative binominal model was conducted when the
data were zero-inflated. IBM SPSS Statistics (version 19)
for Windows was used for the statistical analysis.
Results
Figure 2 shows the trial flowchart. A total of 198 pa-
tients completed the baseline interview, and 69% of the
participants were available at the one-year follow-up. In
total, 31 participants from the IMR group and 33 from
the control group did not participate in the one-year
follow-up. No differences were found in the demo-
graphic and clinical characteristics between the IMR and
TAU groups at the one-year follow-up and Table 2 pre-
sents the baseline demographics on the participants.
Intent-to-treat analyses
Table 3 shows the results of the one-year follow-up,
intent-to-treat analysis, and complete case analysis. In
the GAF-F, a nonsignificant group indicated a difference
of 0.8 in favor of the IMR group (95% confidence inter-
val [CI]: − 4.7 to 3.0 points, t = − 0.42 p = 0.45). Table 3
summarized the analysis of the group means over time
and revealed no significant differences between the IMR
and control groups in clinical recovery symptoms (i.e.,
GAF-S, PSP, PANSS, HAM-D, and YMRS). Analyses of
changes in personal recovery based on the MHRM,
Hope, and Client’s Satisfaction Questionnaire also
showed no differences between the IMR and control
groups between either the baseline and one-year
follow-up or the postintervention and one-year
follow-up time points. As a post hoc analysis, we exam-
ined the time effect and while both groups improved on
functioning and personal recovery, there was no differ-
ences on symptoms and illness management (data not
shown).
Complete case analyses
Similar results were found between the complete case
analyses and the intent-to-treat analyses for the GAF-F,
PSP, and PANSS. Furthermore, no between-group differ-
ences were observed in any of the other assessments, in-
cluding the GAF-S, HAM-D, YMRS, Adult State of
Hope, MHRM, Client’s Satisfaction Questionnaire, or
the two versions of the IMRS.
Service utilization
No significant differences were found in the number of
hospital admissions (mean difference 0.49, 95% CI: 0.67–
Jensen et al. BMC Psychiatry           (2019) 19:65 Page 5 of 12
1.48, p = 1.0), days of hospital admission (mean differ-
ence 19.4 95% CI: -0.76-0.5, p = 0.5), or number of emer-
gency room visits (mean difference 0.63, 95% CI: 0.81–
1.54, p = 0.51) between the IMR and control groups.
Fidelity
The IMR Fidelity mean scores across the three partici-
pating CMHCs assessed half-way at 4 months were
CMHC 1: 4.3 (SD 0.9), CMHC 2: 4.1 (SD 0,1) and
CMHC 3: 4.1 (SD 0.3) indicating good fidelity. The
mean scores at the end assessment were CMHC 1: 4.2
(SD 0.7), CMHC 2: 4.0 (SD 0.8), and CMHC 3: 4.2 (SD
0.9) indicating high fidelity. For further information see
Dalum et al. (2018) [17].
Subgroup and subscale analyses
No association was found between a higher number of
sessions attended and the GAF-F score at the one-year
follow-up (see Table 4). The subgroup analyses showed
no differences in the effect of IMR according to the par-
ticipant diagnosis or sex on the outcomes of the GAF-F,
PSP, or PANSS (see Table 4). We also performed post
hoc analyses to investigate whether specific symptoms
were influenced by IMR, as shown in other trials. When
Fig. 2 Flow Diagram for the Danish Illness Management and Recovery trial
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performing complete case analyses using univariate
ANOVA with postintervention as a covariate, no signifi-
cant difference was found between the intervention and
control groups. A p-value of 0.05 was found for the
PANSS positive symptoms favoring the TAU group;
however, when considering the multiple statistical tests
conducted, this result cannot be considered significant.
We planned to analyze the IMRS as the total scale score
(see Table 3), but post hoc we also analyzed the IMRS as
three-factor solution subscales (the Recovery, Manage-
ment, and Biology scales) [26]; however, the results were
not significant (data not shown).
Discussion
The aim of the present study was to examine the
long-term outcomes of an IMR trial, because the hy-
pothesis behind the IMR program is that clinical and
personal recovery can occur over a considerable time-
frame after attending the program (Fig. 1). Overall, the
study revealed no difference between the IMR and TAU
groups in clinical recovery, personal recovery, illness
self-management, and service utilization at the one-year
follow-up. This result was similar to the findings at the
end of the intervention [17].
Fidelity and exposure to IMR
As mentioned in the introduction, two important issues
should be considered in addition to the RCT design
when interpreting the results: the fidelity of the IMR
program and the participant’s exposure to the IMR pro-
gram. The fidelity assessments showed good implemen-
tation at the program level [32]. The high fidelity can be
explained by that all IMR facilitators went through a
specific course of education prior to the intervention,
had supervision during the intervention and held
planned meetings during the intervention with the re-
search team, leaders of the CMHC and IMR-instructors
to evaluate the implementation of the IMR-program.
Among the participants randomized to the IMR group,
13% did not attend a single IMR session, and 46.5%
attended more than 20 sessions, resulting in an average
session number of 16.4 (SD ±13.3) [17]. We had hoped
for a higher participation rate. This result is a limitation,
although the analyses showed no differences in the out-
comes at the one-year follow-up between the partici-
pants who attended 0–10 sessions and those who
attended 10+ sessions.
Trial results in the context of previous IMR trials
In terms of symptoms, the review by McGuire et al.
(2014) [7] found two RCTs [8, 9] supporting the hypoth-
esis that IMR reduced symptoms, which aligned with the
conclusion of a later study using a modified version of
the IMR program [12]. However, the findings of the
present study align with those of the study by Salyers et
al. (2014) [11]. Thus, the results appear to be contradict-
ory. Currently, a Cochrane review of IMR is being con-
ducted; a meta-analysis will be conducted as part of this
review if the symptom data are adequate, which will pro-
vide a better understanding of the effect of IMR on
symptoms [33]. Furthermore, after a Dutch feasibility
study of the IMR program, the authors proceeded to a
Table 2 Demographic and clinical characteristics of the patients
at the baseline
Baseline
bIMR (N = 99) TAUc (N = 99)
Variable N % N %
Site
CMHCa Ballerup 29 29.3 25 25.3
CMHC Gladsaxe 30 30.3 33 33.3
CMHC Frederiksberg 40 40.4 41 41.4
Sex
Female 45 45.5 44 44.4
Age
Age 41 45
±SD ±11.0 ±11.5
Age range 20–68 22–77
Housing
Rented housing 75 75.8 65 65.7
Cooperative dwelling 14 14.1 18 18.2
Owner-occupied housing 8 8.1 10 10.1
Homeless 0 0
Employment status
Employed 7 7.1 12 12.1
Student 5 5.1 0 0
Unemployed or retired 84 84.8 81 81.8
Education
Public school 26 26.3 26 26.3
High school 17 17.2 17 17.2
Vocational training 18 18.2 18 18.2
University 27 27.3 29 29.3
Living status
Alone 70 70.7 69 69.7
Living with spouse and/or children 19 19.2 26 26.3
Diagnosis
Schizophrenia 76 76.8 75 75.8
Bipolar disorder 23 23.2 24 24.2
Alcohol or drug abuse
Alcohol or drug abuse 15 15.2 13 13.1
No abuse 80 80.8 80 80.8
aCommunity mental health center, bIllness Management and Recovery,
cTreatment as usual
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RCT; the results from this RCT will contribute to clari-
fying the effect of IMR on symptoms [34].
The present study found no effect of IMR on improved
functioning, which was in accordance with the study by
Salyers et al. (2014) [11] but differed from the study by
Levitt et al. (2009) [8]. Altogether, the results raise ques-
tions regarding the impact of IMR on functioning as a
long-term effect. Personal recovery, such as hope [28],
and a person’s experience with recovery (i.e., pursuing per-
sonal goals or taking social initiatives) were measured in
three other trials, none of which reported significant im-
provement for the participants in IMR [9–11]. Therefore,
the results of the present trial are in accordance with these
results and suggest that IMR does not seem to impact the
participants’ personal recovery at the long-term follow-up.
According to the conceptual framework underlying
the IMR program, illness self-management is central for
the ability of individuals to achieve clinical and personal
recovery from mental illness [1]. All five trials assessed
illness self-management with the IMRS. In three of the
trials, both the patient (IMR-patient) and staff
(IMR-staff ) versions were used [8–10]. In contrast to
our study, these three studies reported significant im-
provements resulting from IMR. Because the other RCTs
had methodological limitations regarding the effect of
IMR on illness self-management, examining the effect of
IMR in a meta-analysis to obtain an integrated view of
the effect is important [33]. The review by McGuire et
al. (2014) [7] found that independent-assessor rated out-
comes were more likely to show significant changes, al-
though the present trial did not support these results. In
our study we found time effect in both groups on func-
tioning and personal recovery, but not on symptoms and
illness management, indicating that services and/or time
were generally associated with some improvement but
IMR was not associated with additional benefit. One
possible explanation for our null findings may be that
the IMR-program is not as effective as earlier reviewer
Table 3 Recovery and illness self-management outcomes at the one-year follow-up
Intent-to-treat analysis Complete case analysis
One-year follow-up Postintervention One-year follow-up
IMRa bTAU IMR TAU IMR TAU
N Mean Std.
error
Mean Std.
error
P N Mean SD N Mean SD N Mean SD N Mean SD P
Clinical recovery functioning
GAF-Fc 99 50.6 1.38 49.8 1.40 0.67 62 45.4 12.1 59 43.5 11.8 66 50.4 13.4 62 50.2 11.8 0.63
Clinical recovery symptoms
GAF-Sd 99 50.8 1.54 52.2 1.53 0.50 58 47.1 13.0 54 48.5 13.1 65 51.1 13.5 59 52.7 11.4 0.64
PSPe 99 52.1 1.55 53.1 1.57 0.63 59 52.6 13.4 59 49.6 14.1 64 52.3 14.2 63 53.5 13.1 0.25
PANSSf 99 56.5 1.83 52.8 1.83 0.15 51 57.5 15.4 52 60.4 18.9 55 58.7 18.1 57 57.6 20.7 0.51
Hamiltong 99 6.57 0.44 6.54 0.43 0.96 52 5.81 3.78 53 5.48 4.31 57 6.67 3.69 58 6.45 3.44 0.60
Young’s Maniah 99 8.56 0.75 8.0 0.74 0.47 52 6.77 5.92 53 7.49 6.20 57 8.02 5.34 58 7.43 5.60 0.40
Intent-to-treat analysis Complete case analysis
Personal recovery
Mental Health Recovery
Scalei
99 74.5 2.0 75.2 2.2 0.81 59 69.5 12.2 57 69.2 18.0 49 76.9 16.4 44 78.6 17.3 0.47
Adult State of Hope Scale 99 34.1 1.1 34.9 1.1 0.62 68 32.6 8.3 71 31.8 10.0 52 35.5 7.67 50 34.9 8.64 0.86
Patient satisfaction 99 24.4 0.52 25.3 1.0 0.84 61 24.6 5.1 58 24.8 4.1 55 25.0 4.76 46 25.8 4.0 0.28
Illness self-management
IMRS-Patientj 99 53.4 1.14 54.5 1.10 0.96 46 54.7 7.59 55 52.8 8.1 48 54.0 6.63 44 55.7 7.75 0.16
IMRS-Staffk 99 53.7 1.1 54.1 1.0 0.46 54 55.3 7.0 62 53.5 8.6 41 55.2 5.0 39 55.5 8.21 0.37
aIllness Management and Recovery;bTreatment as usual
c(GAF-F) Global Assessment of Functioning, Possible total scores range from 1 to 100 higher scores indicating higher level of functioning
d(GAF-S) Global Assessment of Symptoms, Possible total scores range from 1 to 100 higher scores indicating lower symptomology
e(PSP) Personal and Social Performance, Possible total scores range from 1 to 100 higher scores indicating better personal and social functioning
f(PANSS) Positive and Negative Syndrome Scale, Possible total scores range from 16 to 112
g(Hamilton) Hamilton Rating Scale for Depression, 6 items, Possible total scores range from 6 to 48 higher scores indicating more severe symptomology
h(Young’s Mania) Young Mania Rating Scale, Possible total scores range from 0 to 60 higher scores indicating more severe symptomology
iMental Health Recovery Scale. Possible total scores range from 30 to 150 with higher scores indicating better recovery
Adult State of Hope Scale. Possible total scores range from 8 to 48, where a higher number indicates greater hope
jIllness Management and Recovery Scale Patient version, kIllness Management and Recovery Scale Staff version. Possible total scores range from 15 to 125 with
higher scores indicating better illness management and recovery
Patient satisfaction. Possible total scores range fromn
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concluded. A recent Cochrane review showed that psy-
choeducational programs affected the participants’
symptom severity but not their daily functioning [35].
IMR is more than a psychoeducational program. In psy-
choeducational programs strategies are considered to be
important for shared decision-making; however, other
behavioral-based illness management strategies are also
included in IMR, such as relapse prevention training
and training in coping skills [36]. The results on the
Cochran review on psychoeducational programs to-
gether with the results from IMR trials indicate the ne-
cessity of considering the need for programs with other
Table 4 Per-protocol and post-hoc subgroup analysis at one-year-follow-up
Per-protocol sub-group analysis
Attendance in IMR 0–10 sessions (N = 20) 10+ sessions (N = 48)
Mean SD N Mean SD N P-value
GAF-F 47.3 13.7 19 51.3 12.8 47 0.26
PSP 48.5 12.5 19 53.4 14.4 45 0.20
PANSS 61.8 19.2 12 57.3 17.4 43 0.44
IMRS-Staff 54.0 5.1 9 54.9 6.9 32 0.73
Per-protocol sub-group analysis IMR° TAU•
Mean SD N Mean SD N P-value
Diagnosis Schizophrenia
GAF-F 47.4 12.2 49 48.6 11.8 52 0.60
PSP 49.4 13.2 48 52.1 13.0 53 0.30
PANSS 61.7 17.5 43 60.5 20.7 47 0.77
IMRS-Staff 53.9 6.3 31 53.1 7.3 31 0.64
Bipolar Disorder
GAF-F 58.1 12.7 17 57.7 8.87 10 0.94
PSP 59.8 13.4 16 60.8 9.83 10 0.83
PANSS 45.9 12.8 12 46.5 10.8 10 0.91
IMRS-Staff 57.1 6.9 10 62.6 3.29 8 0.06
Sex
Male GAF-F 47.4 11.9 39 50.9 12.4 42 0.21
PSP 49.3 12.4 39 54.1 12.9 43 0.09
PANSS 63.1 17.8 33 58.9 21.2 38 0.38
IMRS-Staff 53.0 6.06 24 52.8 7.73 25 0.94
Female
GAF-F 54.0 14.0 27 48.5 10.7 20 0.15
PSP 56.1 15.3 25 52.1 13.1 20 0.36
PANSS 51.0 15.2 22 56.3 17.5 19 0.31
IMRS-Staff 57.1 6.52 17 59.1 5.91 14 0.39
Post Hoc subgroup analysis IMR TAU
Mean SD N Mean SD N P-value
PSP Aggressive behavior 0.58 0.75 62 0.50 0.68 60 0.49
Activities 2.74 0.92 62 2.67 0.81 60 0.24
Relations 2.00 1.24 62 1.97 1.1 60 0.68
Self-care 1.13 0.97 62 1.25 1.0 60 0.46
PANSS Positive 13.3 5.31 52 12.3 5.0 53 0.05
Negative 14.4 6.3 51 14.0 5.87 52 0.63
Psychopathology 31.2 8.75 52 31.2 14.7 53 0.95
о Illness Management and Recovery, •Treatment as usual, (GAF-F) Global Assessment of Functioning, (PSP) Personal and Social Performance, (PANSS) Positive and
Negative Syndrome Scale, Illness Management and Recovery Scale Staff version
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conceptual frameworks to support people with severe
mental illnesses in achieving functional and personal re-
covery. The results of present trial indicate that the
IMR-program’s theoretical foundation, which is listed in
Fig. 1 may be flawed.
Strengths and limitations
The present RCT has several strengths. The trial was
conducted according to the best methods available to re-
duce the risk of systematic, random, and design errors.
The trial was conducted with adequate generation of the
allocation sequence, adequate allocation concealment,
adequate blinding wherever possible, adequate reporting
of all relevant outcomes, and an intent-to-treat-analysis
[37–40]. Moreover, sample size calculations were con-
ducted prior to participant recruitment.
However, the trial also has some limitations. Although
all centers reported high fidelity, reflecting good imple-
mentation of IMR in the CMHCs [32], none scored high
on the fidelity item pertaining to the involvement of par-
ticipants’ families or significant others [32]. A limitation
in the fidelity assessment was that the IMR treatment in-
tegrity scale (IT-IS) to measure the therapeutic skills of
the IMR-instructors or assessment to measure the im-
plementation of IMR at organization level by the Gen-
eral organizational index (GOI-scale) was not applied in
this trial. As previously mentioned, another limitation
was that exposure to IMR was lower than we had hoped.
However, no difference between the non-exposed partic-
ipants (attending 0–10 sessions) and the exposed partici-
pants (attending 10+ sessions) was found at the one-year
follow-up, which was in accordance with the fact that
we also found no postintervention differences between
the two groups. Postintervention, we performed post
hoc analyses to address the exposure issue; however,
none of our findings indicated that this problem had af-
fected our results [17]. The exposure to IMR in the
present study may better reflect a “real-world setting”
than high IMR exposure. We can expect that some par-
ticipants may not want to continue after a few IMR ses-
sions and that some may not be able to participate in all
sessions over a nine-month period. Furthermore, the
waiting time from randomization to the first IMR group
session was, on average, 87 days, which might have af-
fected the results; indeed, providing psychosocial treat-
ment when an individual is interested in and motivated
to participate in such treatment is important. However,
analyses to determine whether this wait affected the re-
sults did not indicate any effect [17]. In the present
RCT, some of the IMR instructors were case managers
for patients in the control group, and therefore, a
spill-over effect in the control group was possible. How-
ever, the IMR instructors were educated to use only the
IMR material for the IMR group participants.
Furthermore, they were told to consult a well-experi-
enced psychiatrist in only performing TAU, in case they
were unsure whether specific elements could be
regarded as part of TAU. A critical limitation is the high
number of incomplete observed data due to a high lost
to follow-up rate. Furthermore, a limitation is that nearly
one-third of the participants did not complete the
self-report instruments a long-term follow-up. To ad-
dress these missing data, a mixed model with multiple
imputations was generated to estimate and improve the
statistical test values. Furthermore, the analyses were
conducted according to the intent-to-treat principle,
with the two-tailed level of significance for all statistical
tests set at 0.05. Because all outcomes were exploratory,
the risk of type 1 error was considerable. However, be-
cause none of the outcomes were statistically significant,
the risk of type 1 error was ruled out. The participants
who did not attend at the one-year follow-up may have
recovered; however, these participants had significantly
more hospitalizations, longer hospital admissions, and
low attendance to the IMR program (see Table 4. When
we conducted the present trial, we might have been too
optimistic, because the trial was based on the number of
participants needed to assess a 6-point difference on the
GAF-F scale postintervention. Therefore, our sample
size may be too small to state whether an observed dif-
ference of 0.8 is in fact a true difference at the one-year
follow-up, but this finding most likely does not have
clinical relevance.
Conclusion
The present study showed no significant effect of IMR
on clinical and personal recovery at the one-year
follow-up. Together with previous RCTs with long-term
follow-up, the findings raise questions about the effect
of IMR on symptom severity. Altogether, the results of
existing RCTs that have investigated IMR raise questions
regarding the impact of IMR on functioning and do not
suggest any effects on personal recovery. One possible
explanation for our null findings is that the
IMR-program is not as effective as earlier reviewer con-
cluded. Hopefully, ongoing research on IMR [33, 41] will
provide a more solid answer on this matter. However,
the results suggest the need to consider the development
of interventions based on other conceptual frameworks
to help people with severe mental illnesses gain a better
level of functioning and achieve personal recovery.
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